Research guide · Metabolic Support
Survodutide — research protocol
Dual GLP-1/glucagon receptor agonist studied for advanced weight management and metabolic regulation.
This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.
Catalog presentations
Concentration table
Mathematical reference only; this is not a dosing recommendation.
Research areas
- Dual GLP-1 + Glucagon receptor agonist
- Next-generation metabolic research compound
- Lyophilized powder for maximum stability
- 99% HPLC verified purity
Most-cited research protocols
Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.
Survodutide is an investigational once-weekly subcutaneous peptide developed for weight loss and MASH. It acts as a dual GLP-1 and glucagon receptor agonist, currently not FDA-approved as of June 2026.
| Dose | Frequency | Duration | Route | |
|---|---|---|---|---|
| Phase 2 obesity trial (lowest studied dose) | 0.6 mg | once weekly | 46 weeks | Subcutaneous injection |
| Phase 2 obesity trial (mid dose) | 2.4 mg | once weekly | 46 weeks | Subcutaneous injection |
| Phase 2 obesity trial (top dose) | 4.8 mg | once weekly | 46 weeks | Subcutaneous injection |
| Phase 3 SYNCHRONIZE-1 trial | Varied, with a slower, more flexible dose increase | once weekly | 76 weeks | Subcutaneous injection |
Cycle: Dose escalation during the first 20 weeks, then steady for 26 weeks (Phase 2); slower and more flexible dose increase in Phase 3.
Benefits and research observations: Side effects were most common during the initial 20-week dose-increase phase, then improved as weight loss continued through 76 weeks, primarily from fat tissue.
Handling and storage
Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.
Warnings
Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.
Published sources
- 1.le Roux CW, et al. Lancet Diabetes Endocrinol, 2024.
- 2.Sanyal AJ, et al. NEJM, 2024.